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Background: With increasing diabetes prevalence worldwide, an impending diabetes “pandemic” has been
reported. However, definitions of incident cases and the population at risk remain varied and ambiguous. This study
analyzed trends in mortality and screening that contribute to diabetes prevalence and incidence, distinguishing
between new incident cases and newly detected cases.
Methods: In an integrated provider-and-payer-system covering 53% of Israel’s population, a composite diabetes
case-finding algorithm was built using diagnoses, lab tests, and antidiabetic medication purchases from the
organization’s electronic medical record database. Data were extracted on adult members aged 26+ each year from
January 1, 2004 through December 31, 2012. Rates of diabetes prevalence, incidence, screening, and mortality were
reported, with incidence rates evaluated among the total, “previously-screened,” and “previously-unscreened” at-risk
populations.
Results: There were 343,554 diabetes cases in 2012 (14.4%) out of 2,379,712 members aged 26+. A consistent but
decelerating upward trend in diabetes prevalence was observed from 2004–2012. Annual mortality rates among
diabetics decreased from 13.8/1000 to 10.7/1000 (p = 0.0002). Total population incidence rates declined from 13.3/
1000 in 2006 to 10.8/1000 in 2012 (p < 0.0001), with similar incidence trends (13.2/1000 to 10.2/1000; p = 0.0007)
among previously-screened at-risk members, and a rise in testing rates from 53.0% to 66.7% (p = 0.0004). The
previously-unscreened group decreased 28.6%, and the incidence rates within this group remained stable.
Conclusions: The increase in diabetes prevalence is decelerating despite declining mortality and increasing
testing rates. A decline in previously-screened incident cases and a shrinking pool of previously-unscreened
members suggests that diabetes trends in Israel are moving toward equilibrium, rather than a growing epidemic.
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Diabetes screening ratesBackground
Diabetes mellitus is a chronic illness that contributes
greatly to overall morbidity and mortality and has been
widely reported to be increasing in prevalence through-
out the world [1]. There have been myriad efforts to
uncover the causes contributing to this trend, including
decreasing mortality rates and resultant aging of the
population, increasing incidence rates, and more effec-
tive detection of diabetes [2-8]. The Centers for Disease* Correspondence: TomasKa@clalit.org.il
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unless otherwise stated.Control and Prevention (CDC) utilizing diagnoses of
diabetes obtained from the 2005–2008 National Health
and Nutrition Examination Survey (NHANES) reports
significant increases in both prevalence and incidence of
diabetes in the United States from 1992 to 2010 [9].
Boyle et al. using US population statistics predicts that
by 2050, 21% of the population will be diabetic [10]. The
global burden and emerging pandemic of diabetes has
been related to increases in obesity, decreases in physical
activity, and the aging of the population [9,11].
Accurate assessment of prevalence and incidence of
diabetes, however, is very much dependent on the data
used to evaluate these trends [12]. In 2012, the LondonLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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countries (Italy, Germany, Spain, United Kingdom, and
France) and reported a paucity of reliable data for na-
tional registries of diabetes incidence and prevalence
[13]. Nevertheless, that survey reported that there was
growing concern in these countries related to increasing
incidence. Well documented diabetes registries from
limited localities in Taiwan, Canada, Denmark, Scotland,
UK, and Italy document a consistent annual increase in
prevalence in all cases, with most also reporting rising
incidence [2,5-7,14,15].
A recent review of conceptual and practical challenges
to the development of diabetes registries highlighted is-
sues of case definition particularly in instances of uncer-
tain gold standards [12]. The authors make the point
that multiple inclusion criteria have to be incorporated
into the case definition to assure high sensitivity in case
identification but should also allow for flexibility by ap-
plying more stringent criteria to account for consi-
derations of specificity. In almost all efforts to capture
diabetes incidence and prevalence, there has been an in-
tegration of any number of different datasets dependent
on the constructs of local data availability and defini-
tions. These include varying combinations of hospital
discharge summaries, outpatient medical records, la-
boratory test results, and medications dispensed. Several
large studies have used data on diagnoses and medica-
tions from medical records, claims-based data, and phar-
macy records [2,7,14]. A few relatively smaller studies
have also had access to data capturing the date of diag-
nostic or screening tests (glucose or HbA1c) and clinical
laboratory results [4,5,15]. These limitations in access to
data impact how diabetes is defined and how new inci-
dent cases are identified.
Defining the prevalence and incidence of diabetes is
particularly challenging, because it is a chronic illness
with an indeterminate latent phase that is often asymp-
tomatic and may go undiagnosed. Therefore, screening
and detection efforts play a part in how the onset of dis-
ease and incidence are defined; however, most studies
reporting on diabetes prevalence and incidence do not
examine screening policies or detection rates as part of
their assessments. In measuring annual incidence rates,
a key point is how the population at risk is characte-
rized. One characterization is to take the entire popula-
tion without a previous diagnosis of diabetes and by the
enumeration of new diagnoses, measure new cases. This
approach does not make a distinction between patients
who have just developed the disease and patients who
have had the disease for some time but were only re-
cently tested for the first time and thus, the disease has
just been detected and labeled as “newly-detected cases”.
Previous research examining diabetes prevalence and in-
cidence does not distinguish between “new incident”cases and “newly-detected” cases in defining their popu-
lation at risk, thereby resulting in ambiguous representa-
tions of incidence.
The present study was undertaken to disentangle the
complexity of factors contributing to diabetes preva-
lence, incidence, and mortality trends in a large, closed
payer-provider health system between 2004 and 2012. In
documenting diabetes prevalence and incidence trends,
our study is the first to examine screening rates and use
a screening-based incidence measure to distinguish bet-
ween “new incident” cases and “newly-detected” cases.
In parallel, to insure full and accurate enumeration of
the diabetes cases in our adult population, an algorithm
incorporating six sets of criteria derived from a large, in-
tegrated clinical and administrative data warehouse was
created and utilized for case identification.
Methods
Data sources and study population
Clalit Health Services (Clalit), the largest integrated
health care service provider and payer system in Israel,
has a comprehensive health care data warehouse which
combines hospital and community medical records, la-
boratory and imaging information, pharmaceutical re-
cords, and Ministry of the Interior vital statistics. There
is universal health care coverage in Israel, and member-
ship turnover within Clalit is less than 1% annually [16],
facilitating the study of population trends over time. The
Clalit membership includes a relatively larger proportion
of minority (27% vs. 21%) and lower socio-economic in-
dividuals compared to the general Israel population, with
39.8% of Clalit’s adult population earning minimum
wage or below in 2011 compared to 38.8% in the overall
population [17]. For the current study, diagnosis infor-
mation from patient electronic medical records (EMR),
blood test results from laboratory records, dispensed
medications from pharmacy records, age and sex data
from demographic records, and mortality statistics were
accessed on Clalit’s diverse population of over four
million patients, which comprise more than half of the
Israeli population. An open cohort was created based on
data extracted on all the adult members aged 26 and
older during each year from January 1, 2004 through
December 31, 2012. The study and use of this data was
approved by Clalit’s institutional review board.
Diabetes case finding
An algorithm was developed incorporating four parame-
ters (HbA1c tests, glucoses tests, diagnoses, and diabetes
medications) into six diagnostic criteria to create a com-
posite definition of diabetes mellitus for case identifica-
tion (Additional file 1: Figure S1). An internal validation
of this algorithm and further elaboration on the de-
rivation of the composite algorithm are presented in
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were those who only had gestational diabetes and did
not meet the diabetes criteria prior to or subsequent to
pregnancy. As there is no documentation for the week
of pregnancy, the pregnancy period was determined as
the 42 weeks before delivery (when a delivery data was
available), 20 weeks before an abortion, or nine months
before and six months after a diagnosis of pregnancy,
when indicated. If a diabetes criterion was identified for
the first time during pregnancy, the patient was indi-
cated as having gestational diabetes and subsequently
excluded from the study’s population. Additionally, no
distinction could be made between type 1 and type 2
diabetes; however, by limiting the population studied to
adults aged 26 and older, we minimize the inclusion of
incident type 1 cases.
Annual diabetes diagnoses from both hospital and
community records (ICD-9 codes 250 and all its subor-
dinate codes 250.x), lab tests from community facilities,
and antidiabetic medication purchases were compiled to
build the composite algorithm comprised of the following
six internally validated diagnostic criteria: 1) Lab Tests -
Glucose ≥11.1 mmol/l (200 mg/dl) once; 2) HbA1c >7.0
once; 3) HbA1c ≥6.5 with a glucose test ≥7.0 mmol/l
(126 mg/dl), 12 months before or three months after the
HbA1c test date; 4) Diagnosis + Lab test - Diabetes diag-
noses (ICD-9 codes 250 and 250.x) with a lab test confir-
mation (Glucose ≥7.0 mmol/l (126 mg/dl) or HbA1c ≥6.5)
within a period of 12 months before the diagnosis or up to
three months after the diagnosis date; 5) Medication + Lab
test- Hypoglycemic drug (Anatomical Therapeutic Chem-
ical classification level 3 codes A10B and A10A) purchase
and a lab test confirmation within a period of 12 months
before the purchase or up to three month after the pur-
chase date (≥7.0 mmol/l (126 mg/dl) or a HbA1c ≥6.5); 6)
Diagnosis +Medication - diabetes diagnosis and a con-
comitant antidiabetic drug purchase within a period of
12 months before and three months after the diagnosis
date. The date of diabetes registry entrance was determined
by the earliest date for which one or more of the algorithm
composite criteria were met (Additional file 3: Table S2).
Analysis
Trends in diabetes prevalence, incidence, screening, and
mortality were reported as crude and age-standardized
rates, using the 2005 overall age distribution of the 26
and older Clalit population as the standard. Annual
prevalence, incidence, and mortality rates were also stra-
tified by 10-year age groups.
Prevalence was defined as the annual number of dia-
betes patients at the end of each calendar year, using the
Clalit composite definition of diabetes, divided by the
total Clalit population (26+) alive at the end of each cal-
endar year, reported per 1,000 members.Mortality rates of members with diabetes were re-
ported annually as a proportion of the population with
diabetes who died over the course of the year out of
those who had diabetes at the beginning of the year.
Diabetes screening rates were evaluated annually, de-
fined as members who had a recorded glucose or HbA1c
test anytime during a given year, divided by the total
non-diabetic population 26 years and older at the begin-
ning of that year, who were not screened in the previous
three years. We used a three-year screening period be-
cause this is the recommended time indicated in the US
guidelines for diabetes screening [18]. The unscreened
population was also examined, defined as those mem-
bers without diabetes who did not have a glucose or
HbA1c test in the previous three years.
For capturing incidence, we examined the total popu-
lation at risk (without diabetes at the beginning of the
year), as well as distinguished between members at risk
who had or had not been screened within the previous
three years. Total population incidence was reported as
the annual new cases of diabetes by the end of the year,
divided by the total population at-risk at the beginning
of each calendar year. Those members that were first
identified as having diabetes and who died during the
same year were not included as cases in the numerator.
“Previously-screened incidence” was defined as new cases
in each calendar year between 2006–2012 among only
the members who received a glucose or HbA1c test
(“screened”) at least once in the previous three years and
who had no indication of diabetes at the beginning of
the year. This was to distinguish patients who had not
undergone tests to detect diabetes in recent years, and
thus, whose diabetes status was not clearly determined
at the beginning of that year, from patients who were re-
cently screened by the beginning of the year and did not
meet the diabetes criteria. To allow for this three-year
screening period, screening-based incidence rates were
calculated annually for 2006–2012 because laboratory
data on serum glucose and HbA1c tests were only reli-
ably available from 2003 onwards in the Clalit database.
“Previously-unscreened incidence” were diabetes cases
identified among only the members who were not
screened in the previous three years and who had no in-
dication of diabetes at the beginning of the year from
2006–2012. All rates of change were evaluated from
2006–2012 to allow for comparisons between parame-
ters, and statistical significance was tested using linear
regression.
Results
The Clalit population aged 26 years and older in 2004
consisted of 2,110,824 members, and in 2012 of 2,379,712
members (a 12.7% increase over the entire study period
and a 9.7% increase from 2006 to 2012) (Table 1). There
Table 1 Diabetes prevalence and mortality from 2004–2012
2004 2005 2006 2007 2008 2009 2010 2011 2012 Change2006-2012b
Total adult populationa 2110824 2137856 2170220 2199626 2229850 2263441 2296171 2338708 2379712 9.7%
Prevalent cases 226855 246434 263135 279240 294117 308042 321091 335232 343554 30.6%
Crude prevalence (×1,000) 107.5 115.3 121.2 126.9 131.9 136.1 139.8 143.3 144.4 19.1%
Age-standardized prevalence (×1,000) 93.5 100.1 105.2 109.9 114.1 117.6 120.5 123.4 124.1 18.0%
Prevalence by age group (×1,000)
26-34y 7.3 7.9 8.4 8.8 9.1 9.3 9.3 9.3 9.4 11.9%
35-44y 31.4 33.9 35.4 36.4 37.0 37.1 36.6 35.8 34.5 -2.5%
45-54y 89.5 95.3 100.0 103.9 107.0 109.9 112.2 114.6 114.4 14.4%
55-64y 176.5 186.7 194.8 202.5 210.1 217.0 223.5 229.6 231.0 18.6%
65-74y 251.2 267.8 281.8 295.9 308.2 317.1 324.9 332.1 333.9 18.5%
75-84y 235.3 259.2 278.6 298.5 317.0 333.9 348.5 363.1 372.2 33.6%
85y+ 152.8 175.1 195.0 215.0 231.9 251.0 266.6 282.0 294.7 51.1%
Age-standardized all-cause mortality of
members with diabetes (×1,000)
13.8 12.4 12.2 12.1 11.6 10.9 10.7 10.5 10.7 -12.3%
Mortality by age group (×1,000)
26-34y 3.4 1.8 1.6 2.8 2.8 1.4 2.4 2.1 1.7 6.3%
35-44y 3.6 2.3 3.5 3.2 2.5 3.1 3.6 2.7 3.0 -14.3%
45-54y 7.3 7.0 6.5 6.8 6.5 6.1 5.7 6.0 6.4 -1.5%
55-64y 14.9 13.6 13.4 13.3 13.3 12.2 11.4 11.2 12.0 -10.4%
65-74y 34.0 31.1 30.8 28.7 28.0 26.9 25.9 25.7 26.0 -15.6%
75-84y 81.0 79.0 74.0 73.0 69.8 66.5 65.2 64.3 64.8 -12.4%
85y+ 222.5 217.7 210.9 211.6 195.8 186.1 179.4 185.5 185.2 -12.2%
aFor Clalit members aged 26 and older bPercent change for years 2006 and 2012 was calculated in order to compare with screening-based incidence data
starting in 2006.
Figure 1 Trends in age-standardized prevalence of diabetes
from 2004 to 2012.
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population age 26 and older) compared to 343,554 cases
in 2012 (14.4% of the Clalit population), with a cumulative
34.3% increase in the crude prevalence rate over nine
years and a 19.1% increase during the period from 2006
through 2012. In 2012, there were 52.2% women in the
Clalit population and the mean age was 50.3 ± 17.3. In
comparison, the subpopulation with diabetes in the same
year comprised 50.8% women and the mean age of the
population with diabetes was 65.5 ± 13.1.
Trends in diabetes prevalence and mortality of the dia-
betes population are presented in Table 1 and Figures 1
and 2. The age-standardized prevalence of diabetes in
the study population increased 18.0% between 2006 and
2012 from 105.2/1000 to 124.1/1000. This trend was sta-
tistically significant with p < 0.0001. The increase in
prevalence was more marked in the older age groups,
with the greatest rise in prevalence in those aged 85 and
older, nearly doubling over the study period. While
prevalence rose overall, the annual rate of increase con-
tinuously slowed over the study period (Figure 1). This
leveling in prevalence rates is seen among all age groups,
particularly in those under age 65 for whom a plateauingrate is observed from 2009 to 2012 (Table 1). Simulta-
neously, during the seven-year period from 2006–2012,
the age-adjusted mortality rates among the diabetes
population fell from 12.2/1000 to 10.7/1000, a relative
decline of 12.3% (p = 0.0002). The age-stratified trends
reveal that there was a gradual and consistent decline in
mortality among adults aged 45 and older. The decline
Figure 2 Trends in age-standardized all-cause mortality among
the diabetes population from 2004 to 2012.
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tality in the general Clalit population (−11.8% over the
same period, p <0.001) (results not shown).
Annual screening rates and incidence trends from 2006
to 2012 are presented in Table 2, examining overall inci-
dence and incidence in subpopulations defined by recent
screening. While the annual proportion of screened indi-
viduals, out of previously-unscreened non-diabetics, in-
creased from 53.0% in 2006 to 66.7% in 2012 (p = 0.0004)
(Table 2 and Figure 3), the absolute number of previously-
unscreened at-risk individuals declined from 576,895 in
2006 to 411,858 in 2012 (−28.6%). A decline in the age-
adjusted incidence rate was observed from 13.3/1000 in
2006 to 10.8/1000 in 2012 (p = 0.0002), with the total at-
risk population growing marginally (5.9%) and the annual
number of incident cases shrinking over the study period.
This downward trend in the incidence rate was inter-
rupted by a relatively sharp increase in 2011 followed by a
sharp decrease in 2012 (Figure 4). The age-stratified inci-
dence rates showed similar trends of a steady and slow de-
cline across the age groups, with the exception of a slight
increase in new cases in 2011, particularly in the 65–84
age groups. Among the previously-screened at-risk po-
pulation, there was a decline in incidence from 2006 to
2012, with rates of 13.2/1000 and 10.2/1000, respectively
(p = 0.0007) (Table 2). The same increase and decrease
over 2011–2012 was observed in the previously-screened
incidence rate (Figure 4). The previously-unscreened
incidence rates remained relatively constant over the
2006–2012 period (p = 0.267) (Figure 4).
Discussion
In the present study we retrospectively apply a com-
posite diabetes case-finding algorithm in an EMR data-
base of a large diverse population and examine several
population-based parameters that inform the trends of
diabetes prevalence. During the study period from 2004to 2012, there was a consistent but gradually diminishing
upward trend in diabetes prevalence, with a crude cu-
mulative increase of 34.3% over nine years. Our findings
demonstrate that the trends in prevalence are driven by
a relative balance between detection, the emergence of
new cases, and increased survival among diabetes pa-
tients. Contrary to the view that there is an ensuing local
diabetes “epidemic”—parallel to the global “pandemic”—
we observe that drivers in diabetes trends are moving to-
ward equilibrium, with a decline in the number of “new
incident” cases (among previously-screened individuals),
a slowing in the number of “newly-detected” cases
(previously-unscreened), and declining mortality rates
among diabetes patients. The most striking of these
trends is that the recorded incidence of new diabetes
cases has decreased by nearly 23% over the nine-year
period, with an even sharper decline among the at-risk
subpopulation that has been previously screened and
did not have diabetes when screened in the past.
Whether these trends are sustained will dictate if the
decade-long upward trend in diabetes continues to slow
or plateau.
The overall increase in prevalence of diabetes observed
in the study population is consistent with prevalence re-
ports from other countries; however, the rate of increase
is slowing in our population compared to the escalating
trends reported in previous research [2,4-7,14]. A ma-
jority of these studies have concluded that increasing
prevalence is attributable to declining mortality and
rising annual incidence [5-8]. Similar to these studies,
mortality rates among diabetes patients in our study
population are gradually declining, but unlike their fin-
dings, overall incidence rates are also declining. Much of
the increase in prevalence in our population over the
period of this study is occasioned by intensified screen-
ing and case finding, as well as the decline in mortality.
Among the previously-unscreened population at risk, in-
cidence rates remain fairly constant, but the overall
number of these “newly-detected” cases is declining as
the pool of unscreened patients is gradually depleted.
The decline in these newly-detected cases is occurring
despite an increase in the rates of annual screening
among those at-risk and previously-unscreened, which
partly explains past upward trends and current leveling
of the prevalence.
The relationship between screening and its impact on
prevalence is further confirmed when looking at the in-
cidence trends in 2011 to 2012 (Figure 4). In 2011, an
organization-wide intensive case-finding program for
diabetes and pre-diabetes was launched in Clalit. This
likely explains the sudden rise and resultant drop of inci-
dent cases observed from 2011–2012. Further analysis
revealed that this jump was predominantly a conse-
quence of the number of HbA1c tests conducted among
Table 2 Diabetes incidence and screening from 2004–2012 for total population parameters and from 2006–2012 for
screening-based parameters
2004 2005 2006 2007 2008 2009 2010 2011 2012 Change2006-2012
Total populationa parameters
Total at-risk populationa at
beginning of year
1891846 1883940 1891392 1907065 1920369 1935712 1955387 1975066 2003464 5.9%
Incident cases 30392 28648 26680 26405 25942 25191 24703 26110 21776 -18.4%
Crude incidence ( 1,000) 16.1 15.2 14.1 13.8 13.5 13 12.6 13.2 10.9 -22.7%
Age-standardized incidence (×1,000) 14.8 14.2 13.3 13.1 12.9 12.6 12.3 13 10.8 -18.8%
Incidence by age group (×1,000)
26-34y 2.2 2 1.9 1.9 1.7 1.7 1.6 1.6 1.6 -15.8%
35-44y 7 6.7 6.2 6 5.6 5.6 5.1 5.2 4.6 -25.8%
45-54y 16.2 15.7 15.2 14.3 14.6 14.3 14.5 15.1 13 -14.5%
55-64y 27.1 25.7 24.2 24 23.7 23.3 23.1 24.1 20 -17.4%
65-74y 34.1 32.6 29.7 30.4 30.1 28.5 27.7 29.9 23 -22.6%
75-84y 30.4 29 26.6 27.4 26.4 25.6 24.3 27 21.1 -20.7%
85y+ 21.7 19.6 18.7 19.3 19.1 18.1 17.1 18.1 16 -14.4%
Screening-based parameters
Annual screening rateb 53.0% 56.4% 60.1% 62.9% 65.3% 66.9% 66.7% 25.8%
Previously-screened (prior 3 years) at-risk
populationa
1314497 1362188 1411353 1466190 1520518 1562205 1591606 21.1%
Previously-screened incident cases (only
those with previous negative screening)
20643 20794 21105 20797 20799 22143 17934 -13.1%
Crude previously-screened incidence
(×1,000)
15.7 15.3 15.0 14.2 13.7 14.2 11.3 -28.2%
Age-standardized previously-screened
incidence (×1,000)
13.2 12.9 12.8 12.3 12.1 12.6 10.2 -23.0%
Previously-unscreened (prior 3 years)
at-risk populationa
576895 544877 509016 469522 434869 412861 411858 -28.6%
Previously-unscreened incident cases 6037 5611 4837 4394 3904 3967 3842 -36.4%
Crude – previously-unscreened incidence
(×1,000)
10.5 10.3 9.5 9.4 9.0 9.6 9.3 -10.9%
Age-standardized previously-unscreened
incidence (×1,000)
14.5 14.9 14.2 14.6 14.2 15.7 15.1 4.0%
aFor Clalit members aged 26 and older.
bPatients, age 26 and older, that received an HbA1c or glucose test in a given year, out of the previously-unscreened (prior 3 years) at-risk population.
Figure 3 Trends in age-standardized annual screening rate
among the at-risk population from 2006 to 2012.
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association between screening intensity and incidence
rates. In an organization like Clalit that is a payer and
provider with long-term—or even lifetime—membership,
there are interventions implemented on various levels
that potentially prevent the onset of diabetes (thereby,
lowering incidence) and possibly extend the lifespan of
patients with diabetes (thereby, lowering mortality rates).
These interventions can also be contributing factors to
the observed trends.
Several limitations are to be considered in our study.
We were not able to quantify all key factors contributing
to the trends in incidence, mortality, and screening rates
due to missing or incomplete data on body mass index,
physical activity, and diet in our dataset. Consequently,
Figure 4 Trends in age-standardized incidence of diabetes from
2004 to 2012.
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patterns, it is not expected that the risk factors or lifestyle
variables would have a direct impact on prevalence be-
yond their impact on the three key components examined
in this study. Additionally, this study is intended to focus
on type 2 diabetes mellitus; however, due to data limita-
tions, we could not distinguish between type 1 and type 2
diabetes in our dataset. In order to minimize the impact
of this limitation in the population we defined, we have re-
stricted the study sample to include only adults over the
age of 25, thus eliminating the majority of members with
type 1 diabetes from our sample. Restricting the sample in
this way would exclude most individuals with type 1 dia-
betes from calculations of incidence, since type 1 is usually
diagnosed at younger ages. Furthermore, because there is
no indication in the Clalit laboratory data whether a given
glucose test was done in a fasting state, some of our cri-
teria used two parameters to augment the diagnostic cri-
teria possibilities. Using two parameters resulted in an
algorithm with relatively higher specificity than sensitivity,
which may have underestimated the absolute incidence
and prevalence rates; however, this should not have had a
significant effect on the trends over time. Finally, the “pre-
viously-unscreened” incidence fails to identify patients
who were not screened but did develop new onset dia-
betes in the year being studied.
The findings in our study may be uniquely identified
in a closed provider-payer system with an unusually
stable and universally-insured population, but neverthe-
less reveals that much of the increase in prevalence re-
sults from improved case finding and declines in
mortality, rather than from persistent and escalating in-
creases in the onset of disease.
Conclusions
In conclusion, we observe that the rise in diabetes preva-
lence is decelerating and incidence is declining—mostevident among the “previously-screened” subgroup—
despite aging of the population and an expansion of
testing among at-risk members. The stability of Clalit’s
patient population, with low membership attrition from
year to year, and the standardization of data reporting in
EMRs used across all care settings within the orga-
nization enables consistency and completeness of the
data, as well as providing the ability to track the impact
of policy changes on case finding. Although there is cur-
rently a lack of uniformity in how measures of preva-
lence and incidence are constructed across studies due
to variations in data availability, we maintain that with
the increasing uptake of integrated EMRs in the United
States and Europe, there will be a shift toward more
standardized and uniform measures of disease burden.
While others have shown diabetes prevalence to be con-
tinuously rising, attributable to both declines in mortal-
ity and increases in annual incident cases, our results
suggest that increasing diabetes screening rates (with at-
tenuating impact due to the diminishing pool of “previ-
ously-unscreened” individuals) coupled with declines in
mortality are driving the increase in prevalence, but an
expansion in incident cases is not observed. With inci-
dence rates greatly influenced by organizational policies
for screening, there is a need to consider organizational
screening guidelines when comparing prevalence and in-
cidence trends across settings and contexts.Additional files
Additional file 1: Figure S1. Algorithm for Diabetes Registry. The eight
identified criteria were consolidated by lumping lab tests together to
form six criteria representing the most robust criteria for identifying
diabetics in the Clalit electronic database. Additional file 1: Figure S1
illustrates the process and order in which each of the six criteria was
applied to the electronic database to establish the composite definition
of diabetes. We applied the most specific criteria first to create the
hierarchy with a total of 480,295 patients identified and included in the
diabetes registry.
Additional file 2: Table S1. Diabetes Prevalence and Incidence Final
PHM July 27 2014. Internal validation of diabetic entry criteria with
subsequent confirmation. In order to determine which diagnostic criteria
we would use to identify members with diabetes, we first applied a
modified version of the current diagnostic criteria as defined by the
American Diabetes Association (ADA) to the Clalit database. This includes
abnormal glucose tests (a. glucose ≥126 mg/dl (7 mmol/l) in a fasting
patient; b. glucose ≥200 mg/dl (11.1 mmol/l) on a casual blood test;
c. HbA1c ≥6.5 (7.8 mmol/l)) confirmed by repeated test within 3–6 months.
Because there is no indication in the Clalit laboratory data whether a given
glucose test was done in a fasting state, we adapted from the ADA the
parameters of glucose >200 mg/dl and HbA1c ≥6.5. We then added to
these two lab parameters both diabetes diagnoses and medications to
augment the diagnostic criteria possibilities. Using these four parameters
we generated 10 criteria, as shown in this table, as case definitions of
diabetes to identify from the Clalit electronic database potential diabetics
between 2004–2012. We then cross-tabulated the entry criteria of each
potential diabetic to determine whether they had any of the 10 subsequent
confirmation criteria in the following three years to conduct an internal
validation. We singled out those entry criteria where members were more
than 80% likely on average (mean%) to have all nine confirmation criteria in
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http://www.pophealthmetrics.com/content/12/1/32the subsequent three years. As indicated in the table (rows 3 and 4)
HgbA1c > = 6.5 (×2) and Glucose > = 126 (×2) had relatively low levels of
subsequent corroboration over time (internal validation) and were therefore
not included in the final algorithm.
Additional file 3: Table S2. Progressive aggregation of cases based on
the hierarchy of criteria used to identify diabetics. The table shows the
total number of cases identified by each criterion displayed in Additional
file 1: Figure S1, as well as the number of new cases that are added
by each.
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